Description:
Aminocaproic Acid is a 6-aminohexanoic acid, which acts as an inhibitor of fibrinolysis.
In injection form it is a sterile solution containing 250mg/ml of Amiocaproic Acid
with Benzyl Alcohol 0.9%, as a preservative. The pH is adjusted to approx. 6.8
Molecular Weight is 131.17
Clinical Pharmacology:
The fibrinolysis-inhibitory effects of aminocaproic acid appear to be exerted principally
via inhibition of plasminogen activators and to a lesser degree through antiplasmin
activity. Renal excretion is the primary route of elimination, whether aminocaproic
acid is administered orally or IV. Renal clearance approximates that of endogenous
creatinine clearance. The half-life for the acid is approximately 2 hours.
Indications - Usage:
Amicaproic Acid is useful in hemostasis enhancement when fibrinolysis contributes to
the bleeding.
Contraindications:
Aminocaproic Acid should not be used when there is evidence of an active intravascular
clotting process. When there is uncertainty as to whether the cause of bleding is primary
fibrinolysis or disseminated intravascular coagulation (DIC), this distinction must be
made
before administering this drug.
NOTE: the following test can be applied to generally differentiate between the two
conditions.
Platelet count is usually decreased in DIC but normal in primary fibrinolysis Protamine
paracoagulation test is positive in DIC: a precipitate forms when protamine
sulfate is dropped into citrated plasma. The test is negative in the presence of primary
fibrinolysis. The euglobulin clot lysis test is abnormal in primary fibrinolysis but
normal in DIC.
Carcinogenesis, Mutagenesis, Impairment of Fertility:
Long-term studies in animals to evaluate these potentials have not been conducted.
However, dietary administration of an equivalent of the maximum human therapeutic
dose given to rats of both sexes has impaired fertility as evidenced by decreased
implantations
litter sizes and number of pups born.
Pregnancy:
Teratogenic effects - Pregnancy Category C. Animal teratological studies have not been
conducted with amicaproic acid. It is also not known whether amicaproic acid can cause
fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are
excreted in human milk, caution should be exercised during its use.
Pediatric Use:
Safety and effectiveness in children have not been established.
For further information please refer to the current PDR or to the reference information
provided with this product.
Dosing Regimens Currently Used in Cardiovascular Surgical
Procedures:
5gm Pre-Skin Incision/5gm ECC Prime/5gm Anes. drip @ 20cc/hr; 10gm Pre-Skin
Incision/10gm ECC Prime/10gm Anes. drip@ 40cc/hr
Created 3/96; Modified 09/05/2005